Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
